The loss of a spouse is often cited as the most traumatic event in a person's life. However, for most people, the severity of grief and its maladaptive effects subside over time via an understudied adaptive process. Like humans, socially monogamous prairie voles (Microtus ochrogaster) form opposite-sex pair bonds, and upon partner separation, show behavioral and neuroendocrine stress phenotypes that diminish over time. Eventually, they can form a new bond, a key indicator of adapting to the loss of their partner. Thus, prairie voles provide an ethologically-relevant model for examining neuromolecular changes that emerge following partner separation for adapting to loss. Here, we test the hypothesis that extended partner separation diminishes pair bond-associated behaviors (partner preference and selective aggression) and causes pair bond transcriptional signatures to erode. Pairs were cohoused for 2 weeks and then either remained paired or were separated for 48hrs or 4wks before collecting fresh nucleus accumbens tissue for RNAseq. In a separate cohort, we assessed partner preference and selective aggression at these time points. Surprisingly, pair bond-associated behaviors persist despite prolonged separation and are similar between same-sex and opposite-sex paired voles. In contrast, we found that opposite-sex pair bonding, as compared with same-sex pairing, led to changes in accumbal transcription that were stably maintained as long as animals remained paired but eroded following prolonged partner separation. Eroded genes are primarily associated with gliogenesis and myelination, suggesting a previously undescribed role for glia in maintaining pair bonds and adapting to partner loss. We further reasoned that relevant neuronal transcriptional changes may have been masked by the prominent transcriptional signals associated with glia. Thus, we pioneered neuron-specific translating ribosomal affinity purification in voles. Neuronally-enriched transcriptional changes revealed dopaminergic-, mitochondrial-, and steroid hormone signaling-associated gene clusters whose expression patterns are sensitive to acute pair bond disruption and loss adaptation. Together, our results suggest that partner separation results in erosion of transcriptomic signatures of pair bonding despite core behavioral features of the bond remaining intact, revealing potential molecular processes central to priming a vole to be able to form a new bond.

Despite significant improvements in cancer immunotherapies, enhancing immunogenicity of non-responsive tumors warrants further investigation. A prior drug screen of ~3,000 compounds identified NU7441, a DNA PK inhibitor, as an effective compound that promotes immunogenicity of various melanoma lines in vitro. In this study, we hypothesized that in vivo combination therapy NU7441, STING-L, and CD40 agonist will enhance tumor immunogenicity resulting in both expansion and increased cytotoxic activity of CD8+TCRβ tumor-reactive TILs in B16 melanoma models. Results obtained by flow cytometry demonstrated that combination treatment 1) significantly increased the ratio of CD8/CD4 TILs, 2) expanded several tumor-reactive TCRβ clones, 3) increased granzyme B production and expression of 4-1BB and PD-1, 4) increased ratio of DC/MDSC infiltration, and 5) potentially identified a novel cytotoxic CD8+CD11c+GR-1+ population. Additionally, the expansion of tumor-reactive TCRs was attributed to DNA-PKi’s ability to both expand and diversify the number of neoantigen transcripts resulting in a broader neoantigen expression profile. RNA-seq identified 27 unique neoantigens as potential novel targets in melanoma immunotherapy. TILs isolated from B16 tumors were co-cultured with dendritic cells transfected with tandem-mini genes, each encoding ~10 neoantigens, and T cells were analyzed by flow cytometry to quantify the TCRβ repertoire and functional response to neoantigens. We demonstrate combination treatment with NU7441, STING-L and CD40 agonist enhance antitumor responses through increased myeloid cell infiltration and sensitization of tumor cells to T cell-mediated killing from an expanded CD8+TCRβ repertoire. Supported by R01CA207913 NCI BX004935-01, VA, Merit Award P30CA046934, NCI Leukemia and Lymphoma Society Department of Defense Gates Grubstake University of Colorado Anschutz Medical Campus Cancer League of Colorado